Lennox-Gastaut Syndrome - Pipeline Review, H1 2016

  • ID: 3774190
  • Drug Pipelines
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics, Inc.
  • MORE
Lennox-Gastaut Syndrome - Pipeline Review, H1 2016

Summary

‘Lennox-Gastaut Syndrome - Pipeline Review, H1 2016’, provides an overview of the Lennox-Gastaut Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome
- The report reviews pipeline therapeutics for Lennox-Gastaut Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lennox-Gastaut Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Lennox-Gastaut Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lennox-Gastaut Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Lennox-Gastaut Syndrome Overview

Therapeutics Development

Pipeline Products for Lennox-Gastaut Syndrome - Overview

Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis

Lennox-Gastaut Syndrome - Therapeutics under Development by Companies

Lennox-Gastaut Syndrome - Therapeutics under Investigation by Universities/Institutes

Lennox-Gastaut Syndrome - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Lennox-Gastaut Syndrome - Products under Development by Companies

Lennox-Gastaut Syndrome - Products under Investigation by Universities/Institutes

Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development

Eisai Co., Ltd.

GW Pharmaceuticals Plc

INSYS Therapeutics, Inc.

Lennox-Gastaut Syndrome - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

cannabidiol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NRP-2945 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

perampanel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Lennox-Gastaut Syndrome - Recent Pipeline Updates

Lennox-Gastaut Syndrome - Product Development Milestones

Featured News & Press Releases

Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals

Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy

Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome

May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome

Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients

Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug

Dec 05, 2014: Eisai Presents New Data on Rufinamide at the 68th Annual American Epilepsy Society Meeting

Oct 15, 2014: U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome

Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome

May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Lennox-Gastaut Syndrome, H1 2016

Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Lennox-Gastaut Syndrome - Pipeline by Eisai Co., Ltd., H1 2016

Lennox-Gastaut Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2016

Lennox-Gastaut Syndrome - Pipeline by INSYS Therapeutics, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Lennox-Gastaut Syndrome Therapeutics - Recent Pipeline Updates, H1 2016

List of Figures

Number of Products under Development for Lennox-Gastaut Syndrome, H1 2016

Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Eisai Co., Ltd.
GW Pharmaceuticals Plc
INSYS Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll